Fludarabine

For research use only. Not for use in humans.

目录号：S1491 别名： FaraA, Fludarabinum 中文名称：氟达拉滨

CAS No. 21679-14-1

Fludarabine (FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂，特异性降低STAT1蛋白质水平（和mRNA水平），而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1032.75	现货
10mg	RMB 810.59	现货
50mg	RMB 2525.07	现货
100mg	RMB 3836.33	现货
200mg	RMB 7289.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Fludarabine发表文献94篇：

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(3):564-579

PubMed: 32130883 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(10):943-954

PubMed: 30150681 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):757-774

PubMed: 30423296 ( click the link to review the publication )

Cell Rep, 2021, 34(1):108584

PubMed: 33406422 ( click the link to review the publication )

Cell Res, 2020, 1-10

PubMed: 33159154 ( click the link to review the publication )

Sci Adv, 2020, 29;6(18):eaax7881

PubMed: 32494661 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107825

PubMed: 32610126 ( click the link to review the publication )

Haematologica, 2020, 16 pii: haematol

PubMed: 32299906 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):34

PubMed: 32296043 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 10;5:34

PubMed: 32284883 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(1):122-133

PubMed: 31836351 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):30

PubMed: 32093731 ( click the link to review the publication )

Exp Neurol, 2020, S0014-4886(20)30337-X

PubMed: 33065077 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Life Sci, 2020, 265:118832

PubMed: 33259866 ( click the link to review the publication )

Cardiovasc Diagn Ther, 2020, 10(4):738-751

PubMed: 32968630 ( click the link to review the publication )

Scand J Immunol, 2020, e12981

PubMed: 33031600 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 4

PubMed: 32248559 ( click the link to review the publication )
Exp Lung Res, 2020, 1-9

PubMed: 33238771 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0228302

PubMed: 32628668 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Front Immunol, 2020, 11:1303

PubMed: 32655571 ( click the link to review the publication )

Microb Pathog, 2020, 142:104112

PubMed: 32126255 ( click the link to review the publication )

Int J Biol Macromol, 2020, 147:616-628

PubMed: 31931060 ( click the link to review the publication )

Cell Mol Immunol, 2020, 10.1038/s41423-019-0345-7

PubMed: 31900460 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(3):292-308

PubMed: 32024640 ( click the link to review the publication )

J Microbiol Immunol Infect, 2020, 25 pii: S1684-1182(20)30001-3

PubMed: 32033858 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):112

PubMed: 32169104 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Mucosal Immunol, 2019, 10.1038/s41385-019-0178-9

PubMed: 31182817 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

PLoS Pathog, 2019, 15(11):e1008037

PubMed: 31725811 ( click the link to review the publication )

Mol Ther Oncolytics, 2019,

PubMed: 30775418 ( click the link to review the publication )

Front Immunol, 2019, 10:1622

PubMed: 31379827 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2618-2633

PubMed: 31911850 ( click the link to review the publication )

J Immunol, 2019, 202(11):3173-3186

PubMed: 30996000 ( click the link to review the publication )

Int J Biol Macromol, 2019, 136:980-993

PubMed: 31220493 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )
Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Gut Pathog, 2019, 11:23

PubMed: 31123503 ( click the link to review the publication )

Immunobiology, 2019, 224(3):388-396

PubMed: 30846331 ( click the link to review the publication )

J Microbiol Immunol Infect, 2019, S1684-1182(18)30306-2

PubMed: 31296484 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(12):1944-1957

PubMed: 31554639 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30317

PubMed: ( click the link to review the publication )

J Cell Biol, 2018, 217(4):1503-1519

PubMed: 29507126 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Oncogene, 2018, 37(17):2270-2284

PubMed: 29391602 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):459

PubMed: 29686406 ( click the link to review the publication )

Br J Cancer, 2018, 118(4):509-521

PubMed: 29348488 ( click the link to review the publication )

Expert Opin Ther Targets, 2018, 22(6):547-557

PubMed: 29702007 ( click the link to review the publication )

Hum Immunol, 2018, 79(12):869-875

PubMed: 30316971 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Neuron, 2017, 96(6):1290-1302

PubMed: 29268096 ( click the link to review the publication )

Nat Commun, 2017, 8:15207

PubMed: 28488695 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Leukemia, 2017, 31(2):340-349

PubMed: 27431016 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Brain Behav Immun, 2017, 60:161-173

PubMed: 27742579 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(5):585-597

PubMed: 28108623 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Clin Immunol, 2017, 175:56-68

PubMed: 27940139 ( click the link to review the publication )

J Cell Biochem, 2017, 118(10):3249-3259

PubMed: 28262979 ( click the link to review the publication )
Inflammation, 2017, 40(5):1726-1734

PubMed: 28656529 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0180244

PubMed: 28665978 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

J Exp Med, 2016, 19;213(10):2209-26

PubMed: 27621415 ( click the link to review the publication )

Cancer Res, 2016, 76(4):818-30

PubMed: 26837767 ( click the link to review the publication )

Int Immunopharmacol, 2016, 36:199-204

PubMed: 27160867 ( click the link to review the publication )

FEBS Lett, 2016, 590(1):53-67

PubMed: 26762170 ( click the link to review the publication )

Biogerontology, 2016, 17(5-6):907-920

PubMed: 27484416 ( click the link to review the publication )

Oncotarget, 2016, 8(31):50570-50581

PubMed: 28881584 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Eur J Immunol, 2015, 45(10):2834-46

PubMed: 26255980 ( click the link to review the publication )

Phytother Res, 2015, 29(7):1088-96

PubMed: 25881570 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):61-9

PubMed: 26044347 ( click the link to review the publication )

Mol Med Rep, 2015, 12(6):7869-76

PubMed: 26497667 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

Basic Res Cardiol, 2014, 109(4):419

PubMed: 24907869 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1512

PubMed: 25375377 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2276-87

PubMed: 25122069 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9952-60

PubMed: 24550394 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

靶点

STAT1 ^[4]
(Vascular smooth muscle cells)

体外研究

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量，并伴随着处于细胞周期S期细胞数量的减少，对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase，-8，- 9和- 3，- 7的剪切，继而诱导PARP的剪切。氟达拉滨以时间梯度增加Bax基因表达，而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时，处理后细胞膜电位降低，61.05%的细胞表达低荧光罗丹明123，而未处理的对照组细胞仅为8.62%^[1]。为提高溶解度，Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine)，在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸（(F-ara-ATP）。该代谢产物抑制了DNA复制的几个关键过程，如DNA合成所需酶，比如核糖核酸还原酶，DNA引发酶，DNA聚合酶，具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶^[2]。通过检测ICAM - 1的表达和IL - 8释放，表明Fludarabine还可以诱导前炎症刺激单核细胞的增加^[3]。Fludarabine对卵巢癌细胞系生长无影响，而它对黑色素瘤细胞系有明显的剂量依赖性抑制^[4]。Fludarabine诱导显著降低STAT - 1磷酸化，但不改变JAK 2活性。磷酸Fludarabine对三种STAT蛋白磷酸化影响不显着。Fludarabine（1.5mg）在处理2天后和7天后显著降低磷酸化STAT - 1和STAT-1总蛋白量^[5]。磷酸化JAK 2在处理后第2天变化不明显，处理后第7天的JAK表达明显受抑制。Fludarabine不影响其他STAT蛋白质，特异性抑制STAT - 1激活以降低血管平滑肌细胞体外增殖。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Jeko-1	NFzFOGRHfW6ldHnvckBCe3OjeR?=	MVGyNEDPxE1?	M3PBfVI1KGh?		NFnWe4JqdmirYnn0d{BmgHC{ZYPzbY9vKG:oIFnEUy=>	NITySYw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0NFcyOid-MkW5OFA4OTJ:L3G+
MV-4-11	NFS0U2tCeG:ydH;zbZMhSXO\|YYm=	MV:yMlUh\|ryP	MmDnOFghcA>?		M4O0XYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NHPJOpc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxNVU5Oyd-MkWxNVE2QDN:L3G+
THP-1	MoLQRZBweHSxc3nzJGF{e2G7	MXuyMlUh\|ryP	MX60PEBp		NVvs[GdicW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	M{HrdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
MOLM 13	NYKyOGtmSXCxcITvd4l{KEG\|c3H5	NVPlN\|JrOi53IN88US=>	NEjIUWU1QCCq		MnnUbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTFzMUW4N{c,OjVzMUG1PFM9N2F-
KBM3/Bu2506	NFrQVoFCeG:ydH;zbZMhSXO\|YYm=	MojENk42KM7:TR?=	MUC0PEBp		MkLkbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	M{DkXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
Nalm-6	NXzKOnlFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWW1e5hGUUN3ME2xPEDPxE1?	NEjlXlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Reh	MmnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljDTWM2OD1\|MDFOwG0>	NX\DPGc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
U2937	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTKTWM2OD1zNjFOwG0>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Mec-1	MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYX3d5FrUUN3MP-8olUxOCEQvF2=	NUX0dpdxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
RPMI-8226	NWXYT3dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{\BW2lEPTB;NUCwJO69VQ>?	MmX2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Molt-4	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3zrc2lEPTB;MUiwJO69VQ>?	M123PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
Nalm-6-FluR	M3iyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfLfY9KSzVyPUK1NEDPxE1?	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB4MUGwNUc,OjVyNkGxNFE9N2F-
Raji	M2DpTGZ2dmO2aX;uJGF{e2G7	NIPVNYc{yqEQvF2=	MmPkNlQwPDhxN{KgbC=>		MVfpcoR2[2W\|IHHjZ5VufWyjdHnvcpMhd2ZicEWzMEBxPjNiYX7kJJA4O8Li	MnXqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7NEC2PVUoRjJ2OUSwOlk2RC:jPh?=
PBMC	NEnGd2hHfW6ldHnvckBCe3OjeR?=	MYK1NE8yODBizszN	NX3kcpdjOjRiaB?=	NXLvUXo{TE2VTx?=	M1TTO4lvcGmkaYTzJHNVSVRzIIDoc5NxcG:{eXzheIlwdg>?	NFLqO\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
MDA-231	M3OzSWZ2dmO2aX;uJGF{e2G7	MmnENVAxKM7:TR?=	NVLPT2M3OjRiaB?=	NXjxRmlyTE2VTx?=	NUWwU3dR\GWlcnXhd4V{KEmGTzDlfJBz\XO\|aX;u	MlPLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
624.38mel	Ml63SpVv[3Srb36gRZN{[Xl?	NEXmPWI2OCEQvF2=	MX[yOEBp	MXrEUXNQ	M4fVeIRm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?=	MmW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
MDA-231	NHi5dI5HfW6ldHnvckBCe3OjeR?=	NGLHUFY2OC1{MECg{txO	NXPCe4RrOjRiaB?=	NFXEUZRFVVOR	NVzsemt4cW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO=	NW\ISJRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
624.38mel	NIXYTGdHfW6ldHnvckBCe3OjeR?=	NHPxXWE2OC1{MECg{txO	NFnwV4czPCCq	M3PlZWROW09?	NYr4SYVpcW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO=	NUCzW2t2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
HMECs	M36yfWZ2dmO2aX;uJGF{e2G7	NVnhdIwyOTBywrFOwG3DqA>?	NIi5WXM{PsLiaB?=		M3rlcIlvcGmkaYTzJGlHVs7\|wrDhcoQhVFCVIHnu[JVk\WRiU2TBWFEheGixc4Doc5J6dGG2aX;uJIFv\CCLUl[xJIV5eHKnc4Ppc44>	M4jSdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MkGxN\|I4Lz5{NEKxNVMzPzxxYU6=
HMECs	NEPSPW9HfW6ldHnvckBCe3OjeR?=	NEftVXgyODEEoN88UeKh	M1nB[VM3yqCq		NG\oeIZqdmirYnn0d{BKTk8QsdMgcYVlcWG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJHNVSVRzIHHu[EBUXEGWMzygZpV1KG6xdDDv[kBUXEGWMh?=	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJzMUOyO{c,OjR{MUGzNlc9N2F-
BJAB	MlXCRZBweHSxc3nzJGF{e2G7	M37jd\|XDqM7:TR?=	NELUU3EzPCCq		NGPmdmlqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NV;pR\|c2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOVcyPDdpPkK0NFU4OTR5PD;hQi=>
I-83	M1vzSWFxd3C2b4Ppd{BCe3OjeR?=	NF7OR2Y2yqEQvF2=	MlrDNlQhcA>?		NFTrNm1qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB3N{G0O{c,OjRyNUexOFc9N2F-
NALM6	NI\YWo9CeG:ydH;zbZMhSXO\|YYm=	M1\o[lXDqM7:TR?=	NGridHAzPCCq		NFPTO3JqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	Mn30QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNUexOFcoRjJ2MEW3NVQ4RC:jPh?=
DU-145	MmPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\IV\|IxNTFyIN88[{9udA>?	NIrHZpU1QCCqwrC=		MWPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NUPVXlNDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|Q5OTVpPkKzO\|M1QDF3PD;hQi=>
Nalm-6	MUTGeY5kfGmxbjDBd5NigQ>?	NIXTN28yOMLizszN	NH\JPWIyNzJxNDDo		MWPpcoR2[2W\|IHH1eI9xcGGpeR?=	M2fMV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkixNlI{Lz5{M{[4NVIzOzxxYU6=
Reh	MUjGeY5kfGmxbjDBd5NigQ>?	MYCxNOKh\|ryP	M3\rSlEwOi92IHi=		NF7IOYhqdmS3Y3XzJIF2fG:yaHHnfS=>	Mk\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4OEGyNlMoRjJ\|NkixNlI{RC:jPh?=
Nalm-6	NYrFbHhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LQcGlEPTBi4pk8NVDjiIoQvF2=	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
Reh	NVm3d4c6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoryTWM2OCEkiMyxNQKBkc7:TR?=	NETjTYk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NVIzOyd-MkO2PFEzOjN:L3G+
HEC1A	NIC1ZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rPeVExOC13MECg{txO	MYWyOEBp		MXnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
AN3CA	NEnF[IRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUixNFAuPTByIN88US=>	MmTMNlQhcA>?		MnPDbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M3XU[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
HEC50B	M{PDeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPpNVAxNTVyMDFOwG0>	MYSyOEBp		NHnxRVJqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
HEC1A	M{PyVWFxd3C2b4Ppd{BCe3OjeR?=	MVOyNE8yODBizszN	NUWxRYk6OjRiaB?=		M2jNdIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV7NU[5O{c,OjN3OUW2PVc9N2F-
AN3CA	NX23bFZ[SXCxcITvd4l{KEG\|c3H5	Ml7VNlAwOTByIN88US=>	M1PneVI1KGh?		MV7pcoR2[2W\|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NFLvTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OVY6Pyd-MkO1PVU3QTd:L3G+
HEC50B	M1fTfWFxd3C2b4Ppd{BCe3OjeR?=	NFPZWGszOC9zMECg{txO	NXThXGd{OjRiaB?=		NVLYXmVxcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	NYe1flFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
EHEB	M{D0eWFxd3C2b4Ppd{BCe3OjeR?=	Mln6OFAh\|ryP	M3H4clI1KGh?		NYLJOWRtcW6mdXPld{BieG:ydH;zbZM>	M372TFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NEm3NFc2Lz5{M{S5O\|A4PTxxYU6=
A549	NHzOOVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXXVdHVlUUN3ME2xOU44yrF{LkigxtVO	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5N{G5Nkc,OjN\|N{exPVI9N2F-
A549 GAPDH-deficient	MnT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3SwV2lEPTB;MUiuOeKyOi5\|INM1US=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5N{G5Nkc,OjN\|N{exPVI9N2F-
CLL	MVzBdI9xfG:\|aYOgRZN{[Xl?	Mn7HNVAh\|ryPwrC=	Moj4NlQuQTZiaB?=		NHWx[JRqdmS3Y3XzJIFxd3C2b4TpZ{Bk\WyuIHTlZZRp	NX3zWnQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKyNFc3QDZpPkKyNlA4Pjh4PD;hQi=>
MEC1	NWXYdYVOSXCxcITvd4l{KEG\|c3H5	M4THUFExOMLizszN	Mn;pO\|IhcA>?		NF3RcWdqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M2C0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MUOyPVc{Lz5{MkGzNlk4OzxxYU6=
U937	NFTRUHZCeG:ydH;zbZMhSXO\|YYm=	NInSfogxNjhizszN	MkewOE01QCCq		MnzzbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	Mnm5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyN{S3NFAoRjJ{MEe0O\|AxRC:jPh?=
U937	MnjHRZBweHSxc3nzJGF{e2G7	NEn0ZnIyKM7:TR?=	MnXLPVYhcA>?		M2P0Wolv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NX3RZ2R6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlM2OjNpPkKyNFI{PTJ\|PD;hQi=>
Daudi	NVLGT2E6SXCxcITvd4l{KEG\|c3H5	MlfqNlAh\|ryP	MWS5OkBp		NITPZVRqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	NHPjbJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCyN\|UzOyd-MkKwNlM2OjN:L3G+
J45.01	MYnBdI9xfG:\|aYOgRZN{[Xl?	NXL4VZQ6OSEQvF2=	M1rHWlk3KGh?		MlfVbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	M2XQdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MEKzOVI{Lz5{MkCyN\|UzOzxxYU6=
RPMI 8226	NE\Pe4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV7JR\|UxRTJ3LkpCpOKyyqB\|Lkeg{txO	Mm\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEiyOlQoRjJzOUS4NlY1RC:jPh?=
CEM	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4X5NmlEPTB;Mj60xsDDucLiMD60JO69VQ>?	NFS2W2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
Raji	NFn0cFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHWRlBnUUN3ME2wMlQ4yqEEsdMgNE4xPCEQvF2=	NWXSUm9CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
U937	M133Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkDJTWM2OD1yLkK0xsDDucLiMD6wOEDPxE1?	NESxUWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
K562	Mmq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTBwNEVCpOKyyqByLkC1JO69VQ>?	MlP5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NEiyOlQoRjJzOUS4NlY1RC:jPh?=
NALM-6	MWnBdI9xfG:\|aYOgRZN{[Xl?	MXexNEDPxE4EoB?=	NUi2WYY1OjRiaB?=		NEnrbmVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPsbYdpfGy7	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ7OUO4N{c,OjF4OUmzPFM9N2F-
JMV-3	NE\nPW9CeG:ydH;zbZMhSXO\|YYm=	NUnVZ4t{OTBizszNxsA>	MUGyOEBp		MYPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOuaXfoeIx6	NUfzXYx6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG2PVk{QDNpPkKxOlk6Ozh\|PD;hQi=>
EHEB	M1[2Z2Z2dmO2aX;uJGF{e2G7	MmH6OU02OCEQvF2=	NX\G[VFIOjRiaB?=		MoSy[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:wIIPp[45q\mmlYX70cJk>	NHfYcGc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUG2PFM6OSd-MkGxOlg{QTF:L3G+
JVM-2	M2LzZmZ2dmO2aX;uJGF{e2G7	NWe3TItsOzBizszN	Mk\BNlQhcA>?		M{juU4Rm[3KnYYPld{BxOjFiZYjwdoV{e2mxbh?=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTF4OEO5NUc,OjFzNkizPVE9N2F-
KBM3/Bu2506	M4Hl[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|IxRTBwNkegxtVO	Mn3WQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{O1NFkoRjJyOUOzOVA6RC:jPh?=
KBM3/Bu2506	NVnqb3VNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTVVXIxNjZizszN	MkLGNlQhcA>?		M3HFcYlv[3KnYYPld{B1cGViY3XscEBnemGldHnvckBqdiCVLYDoZZNm	NX3Zc5VjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC5N\|M2ODlpPkKwPVM{PTB7PD;hQi=>
MDA-MB-231	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVK1RotuUUN3ME20MlAh\|ryP	MnXGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NEezPVAoRjJyNES3N\|kxRC:jPh?=
MCF-7	NHrLe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHWb5l4UUN3ME2xOU4xKM7:TR?=	NIfHRnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MES0O\|M6OCd-MkC0OFc{QTB:L3G+
HLE-B3	M{K0SmZ2dmO2aX;uJGF{e2G7	NEX3TmgzPSEQvF2=	MoTTOFghcA>?		M4nGdIJtd2OtczDJSm4u\|rQkgKPpcoR2[2WmIGPURXQyKHCqb4PwbI9zgWyjdHnvckBidmRiSVTPJIV5eHKnc4Ppc44>	NEnSSGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MESzOVE2QCd-MkC0N\|UyPTh:L3G+
K562	NVvDTXVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NV\pTotYPzJiaB?=		MUXJR\|UxRTNwMzDuUS=>	M3TlOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{C3NVk5Lz5{MEOwO\|E6QDxxYU6=
BW-225	M1fMPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFzFfZFKSzJyPUGuN\|chy5dzMPMIlljDqM7:TdMg	NX\5S41QRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
OH-65	Mn3lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|IxRTFwM{egx7cyOOLKkklCpO69VcLi	M1f2UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
GR-145	NXLuZW1FT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4rHXWlEOjB;Mj63OEDEnyBzMPMIllghKM7:TdMg	M4nXW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
A549	NXLQNnRCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\LTWMzOD13LkS4JOOYKDFy4pkSPEDPxE4EoB?=	NV;vSXJQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2OlE{QDBpPkG4OlYyOzhyPD;hQi=>
CaSki	MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHrEdmVKSzJyPUGuN\|chy5diMUFijLI4KM7:TdMg	M{\PdFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
ZMK-1	Mnm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzqTWMzOD1zLkO3JOOYKDFy4pkSOkDPxE4EoB?=	M3TMTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
SKW6.4	M4\IfGFxd3C2b4Ppd{BCe3OjeR?=	MViwMlAyNTFyIN88US=>	M4f4OlI1NzR6IHi=		NIrUXXhqdmS3Y3XzJINmdGxiZHXheIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT2g[IVx\W6mZX70JI1idm6nch?=	Ml:2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOThyOUKzOFAoRjF6MEmyN\|QxRC:jPh?=
RPMI 8226	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3rzO\|I1KGh?		NXHVPIVGUUN3ME2xMlU1yqEQvF2=	NHqzeXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m3OlE5Pid-MUe5O\|YyQDZ:L3G+
MM.1S	MoHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		Mn\POFghcA>?		MVjJR\|UxRTF\|LkS4xsDPxE1?	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl5NkG4Okc,OTd7N{[xPFY9N2F-
MM.1R	NX\kWmpDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlvwOFghcA>?		Mn3UTWM2OD1\|Mz63PUDPxE1?	NF3UV2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m3OlE5Pid-MUe5O\|YyQDZ:L3G+
U937	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\xTWM2OD1\|LEKwNEDDuSB3NkCgcm0>	NFv6VJU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUmzNFM3OSd-MUW5N\|A{PjF:L3G+
CLL5	NF\UdYtCdnSrdIXtc5Ih[XO\|YYm=		MYG0PEBpenN?		M3;ROWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDViY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDBwMU[g{txONg>?	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
K562	NEW1enVEgXSxdH;4bYNqfHliYYPzZZk>		NF\JUpo4OiCqcoO=		Ml;UR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gdIFkdGm2YYjlcE1z\XOrc4ThcpQhUzV4MjDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5{NjFOwG0v	M3rZVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
CLL3	MkfZRY51cXS3bX;yJIF{e2G7		MV60PEBpenN?		NXLF[HlTSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS0yOMzDj[YxteyCrc3;sZZRm\CCocn;tJGNNVCCyYYTp[Y51KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBHSUOVIHHuZYx6e2m\|LDDFR\|UxKD1iMD6zOUDPxE1w	NUXoTGpERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CLL4	M{PWb2FvfGm2dX3vdkBie3OjeR?=		MoXiOFghcHK\|		MnLxRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNPCClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOC54NDFOwG0v	NYizVYxYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CEM-DNR-B	NHTzb5REgXSxdH;4bYNqfHliYYPzZZk>		Mn;jO\|IhcHK\|		M33DZWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVS2GTmKtRkBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMT6wNUDPxE1w	NF7Xems9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[wOVY2Pid-MkC2NFU3PTZ:L3G+
primary CLL	NISzUItEgXSxdH;4bYNqfHliYYPzZZk>				NFHrUHlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxemmvYYL5JGNNVCClZXzsd{whVER3MDC9JFEvOSEQvF2u	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF2OEO5Nkc,OjVzNEizPVI9N2F-
CLL6	NVnlfWtxSW62aYT1cY9zKGG\|c3H5		MYG0PEBpenN?		NF;kWGhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBEVEx4IHPlcIx{KGm\|b3zheIVlKG[{b32gR2xNKHCjdHnlcpQh[XO\|ZYPz[YQh[XNiY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JGZCS1NiYX7hcJl{cXNuIFXDOVAhRSBzLk[g{txONg>?	Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CLL2	M2TrRmFvfGm2dX3vdkBie3OjeR?=		M2iy[lQ5KGi{cx?=		MlTiRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOiClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOi54NjFOwG0v	NU\2e5I5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
HCT116	NWT1VWxVS3m2b4TvfIlkcXS7IHHzd4F6		NGnFT3M4OiCqcoO=		NXTqdWFvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB4Lk[g{txONg>?	M3rxV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[yNlc4Lz5{NUS2NlI4PzxxYU6=
PBMC	M1;JNWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXjyb3l[PDhiaILz		NYqyNIhkS3m2b4TvfIlkcXS7IHHnZYlve3RicHH0bYVvfCCSQl3DJIFnfGW{IES4JIhzeyCkeTDD[YxtXGm2cnWtRox2\SCjc4PhfUBqdiCycnXz[Y5kKG:oIH3veZNmKE1{MUDCOEBk\WyuczygTWM2OCB;IEGwJO69VS5?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV4MkSxO{c,OjV3NkK0NVc9N2F-
CHO	NYPOfW1RTnWwY4Tpc44h[XO\|YYm=				Mmf6Rolv\GmwZzDh[oZqdmm2eTDk[ZRmem2rbnXkJIJ6KGSrc4DsZYNmdWWwdDDv[kB{eGWlaX\pZ{BjcW6maX7nJI9nKFtzMkXJYW4uMDRvYX3pco8uOy2rb3TvdIhmdmW2aInsLU1i\GWwb4PpcoUhcW5ibXXtZpJidmW\|IH;mJGNJVyClZXzsd{B{fGGkbImgeJJidnOoZXP0[YQhf2m2aDD0bIUhemG2IHHk[Y5we2mwZTDBN{Bz\WOncITvdkwhU2liPTCxNE41KM7:TT6=	NXj2ZWQ{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxN{ewO\|MzOCd-N{ewO\|MzODxxYU6=
JVM2	MmSxRY51cXS3bX;yJIF{e2G7				MV\BcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCMVl2yJINmdGy\|IHHzd4V{e2WmIHHzJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSCIQVPTJIFv[Wy7c3nzMEBGSzVyIE2gNVAvPCEQvF2u	NX;JS\|N6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
HeLa	MXnBcpRqfHWvb4KgZZN{[Xl?				M{H2eGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZpkhVVSWIHHzd4F6NCCHQ{WwJF0hOTZizszNMi=>	NF;SVoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3N\|c{QSd-MkS2O\|M4Ozl:L3G+
CLL1	NH\LVmdCdnSrdIXtc5Ih[XO\|YYm=		MnzaOFghcHK\|		NYjY[mR1SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhS0yOMTDj[YxteyCrc3;sZZRm\CCocn;tJGNNVCCyYYTp[Y51KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFQ5KGi{czDifUBHSUOVIHHuZYx6e2m\|LDDFR\|UxKD1iMUeuNUDPxE1w	NYe4Z2ZpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CEM	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=		MWe3NkBpenN?		M{DCeGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVkvPDlizszNMi=>	NWH6UFhnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
T47D	NXThd3VGS3m2b4TvfIlkcXS7IHHzd4F6		MUG3NkBpenN?		NEDRfmFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBVPDeGIHPlcIx{KGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUA1Pi5{IN88UU4>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR4MkK3O{c,OjV2NkKyO\|c9N2F-
A549	NEDhRmJEgXSxdH;4bYNqfHliYYPzZZk>		MlzTO\|IhcHK\|		MlSxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOFcvPDRizszNMi=>	M3L3OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
CCRF-CEM	MYHGeY5kfGmxbjDhd5NigQ>?	NVK5W2NUOTBidV2=	M4n4cVEhfG9iNkCgcYlvew>?		MX\EdpVoKHS{YX7zdI9zfCCrbjDoeY1idiCFQ2LGMWNGVSClZXzsd{Bie3Onc4Pl[EBieyCHTmSxMY1m\GmjdHXkJJVxfGGtZTDheEAyOCC3TTDh[pRmeiBzIITvJFYxKG2rboOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXN?	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN6OEewOUc,OjN\|OEi3NFU9N2F-
TC32	NWjydppyeUiWUzDhd5NigQ>?				Mki2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	M3\NXZFJXFNiYYPzZZk>				Mnr2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFVvMjDPV{Bk\Wyucx?=	NIfGfmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NFXyTVFyUFSVIHHzd4F6				M{nn[ZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCDNkezJINmdGy\|	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NFLwSItyUFSVIHHzd4F6				MnzqdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	Mk\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NUnQUmpyeUiWUzDhd5NigQ>?				MUfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	M2W0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	M1nLeJFJXFNiYYPzZZk>				NFrzO5ZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	M4PiSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MnnldWhVWyCjc4PhfS=>				NHrkNJZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	M4HYelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH	NXfrcZFWeUiWUzDhd5NigQ>?				MnfQdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	M13kUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	NV3BUHdneUiWUzDhd5NigQ>?				MlPUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	NYTON5JteUiWUzDhd5NigQ>?				NULGS3I4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NUG0e\|k{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	MoPvdWhVWyCjc4PhfS=>				MUPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy\|	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MmTqdWhVWyCjc4PhfS=>				MmrJdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	Ml;jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	MUXxTHRUKGG\|c3H5				Mmi1dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM>	NGHpfG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	NYTRVGZFeUiWUzDhd5NigQ>?				NX\BbFQxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
NB-EBc1	NHrSWYNyUFSVIHHzd4F6				MVHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	NY\2eoF1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH	MnTPdWhVWyCjc4PhfS=>				MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	M4jLcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NGSzfnlyUFSVIHHzd4F6				M{\UOpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	NH64Z3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	NXPwO5dVeUiWUzDhd5NigQ>?				NYG3PG9ueUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl?	M3fwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	M1;mTpFJXFNiYYPzZZk>				MlnOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOzdiY3XscJM>	NH;wXWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MWfxTHRUKGG\|c3H5				NFrtNnJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	MnTQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	NXjvcopTeUiWUzDhd5NigQ>?				MUjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	M1LCTpFJXFNiYYPzZZk>				M{HadJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHUuOiCRUzDj[Yxtew>?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	M{jlUZFJXFNiYYPzZZk>				MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM>	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	NHjxW2xyUFSVIHHzd4F6				NFLueWZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	M2nQS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MnfzdWhVWyCjc4PhfS=>				NG\6fJlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTTCClZXzsdy=>	M{TW[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Daoy	MkL1dWhVWyCjc4PhfS=>				NGTqfmlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKESjb4mgZ4VtdHN?	M2PrWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
TC32	MXTxTHRUKGG\|c3H5				MV7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	NE[2V2o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	M3XI[pFJXFNiYYPzZZk>				MknzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NXHwV295RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	MUfxTHRUKGG\|c3H5				MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGII\pZYJqdGm2eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	NUX2dWxWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SJ-GBM2	MXLxTHRUKGG\|c3H5				NESwUpFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	M4OwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NHjBN3RyUFSVIHHzd4F6				M3rRdJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M1vGfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MXHxTHRUKGG\|c3H5				M3;HSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz	NIrXUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MUHxTHRUKGG\|c3H5				MkXUdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NWK5eXQ1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh18	NIrUb3ZyUFSVIHHzd4F6				NXr3R3ZQeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MnrGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	MXjxTHRUKGG\|c3H5				NFf1[nhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSjF4NEOgZ4VtdHN?	M33uVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NHGwZmtyUFSVIHHzd4F6				MVnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNU2FIHPlcIx{	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MlS3dWhVWyCjc4PhfS=>				M2HXS5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNLNUeETUKgZ4VtdHN?	NWTobFRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	NHqz[VRyUFSVIHHzd4F6				NI\4d3dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	NGLzXJlyUFSVIHHzd4F6				M1WwWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOThiY3XscJM>	MoL6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	M4e0RpFJXFNiYYPzZZk>				MlzzdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{	Mlv6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MVvxTHRUKGG\|c3H5				M4OweZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KE:{dHjv[49v[WxiM1Sgeoli[mmuaYT5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	Mm\QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	M{TGN5FJXFNiYYPzZZk>				NHjZc2NyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{	MljXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	procaspase-9 / procaspase-3; PubMed: 27223263 Oncotarget Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control. p-p53 / p53; PubMed: 27223263 Oncotarget (A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒ STAT1; PubMed: 26677135 Int J Mol Med Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.	27223263 26677135
Immunofluorescence	α-SMA / Vimentin; PubMed: 28322315 Sci Rep FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).	28322315
Growth inhibition assay	Cell viability ; PubMed: 24956101 PLoS One CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.	24956101

体内研究

PBS对照组中肿瘤细胞增长迅速，25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。^[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

细胞实验： ^[1]	- 合并 Cell lines: 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系 Concentrations: 2 μg/Ml Incubation Time: 24 小时 Method: 对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 10⁵细胞密度铺板，实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定，离心后用含100μg/mL核糖核酸酶PBS重悬浮，37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中，用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL（末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记）法和原位细胞凋亡检测试剂盒处理细胞，最后用流式细胞仪分析。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠 Dosages: 40 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	57 mg/mL (199.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% propylene glycol, 5% Tween 80, 65% D5W	30 mg/mL (suspension)

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Fludarabine SDF

分子量	285.23
化学式	C₁₀H₁₂FN₅O₄
CAS号	21679-14-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	FaraA, Fludarabinum

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04526795	Not yet recruiting	Drug: Cytarabine\|Drug: Fludarabine\|Drug: Pegcrisantaspase	Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent T-Cell Prolymphocytic Leukemia\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	December 31 2020	Phase 1
NCT03832127	Not yet recruiting	Drug: 18F-Fludarabine	Myeloma	Nantes University Hospital\|Cyceron	April 1 2019	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to re-suspend and deliver the inhibitor for in vivo experiments?
回答：
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

研究领域

产品类型

定制您的化合物库

Fludarabine

客户使用Selleck生产的Fludarabine发表文献94篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Fludarabine SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-01-06)

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品